Clarivate Epidemiology’s coverage of dermatitis comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dermatitis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s dermatitis forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with dermatitis?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of dermatitis?
- Of all people with dermatitis, how many in each country have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dermatitis over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology provides at least ten years of forecast data for the following dermatitis populations:
- Total 12-month prevalent cases.
Note: Coverage may vary by country.
Misba Farooq
Misba Farooq, B.P.T., M.P.H., is an associate epidemiologist at Clarivate. Previously, she worked as a hospital-based physiotherapist. She received her master’s degree in public health / social epidemiology from the Tata Institute of Social Sciences and has a bachelor’s degree in physiotherapy from Jammu College of Physiotherapy in India.
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.